alpha-aminopyridine has been researched along with Metastase in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 33 (62.26) | 24.3611 |
| 2020's | 19 (35.85) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T | 1 |
| Kinoshita, T; Sakurada, A; Sakurai, T; Seki, H; Shimizu, K | 1 |
| Johnston, SR; Lee, KA; Shepherd, ST | 1 |
| Cong, L; Dong, J; Ke, M; Li, Y; Lv, Y; Wang, X; Zhang, Z; Zhao, S; Zhu, Y | 1 |
| Kiely, BE; Mok, K; Moylan, E; Nguyen, R; Wilson, BE | 1 |
| Bascialla, L; De Giorgi, A; Gallerani, E; Giaquinto, A; Grigioni, E; Gueli, R; Marrazzo, C; Nigro, O; Pinotti, G; Vallini, I | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| Ball, S; Sultan, A; Swarup, S; Thein, KZ | 1 |
| Aruga, T; Chiu, J; Gazdoiu, M; Gounaris, I; Han, Y; Ishikawa, T; Ito, Y; Ji, Y; Kim, SJ; Masuda, N; Saeki, T; Saito, M; Su, F; Toyama, T; Yap, YS | 1 |
| Fukuhara, K; Goto, Y; Hayashi, H; Hida, T; Morise, M; Nagasawa, T; Niho, S; Nishio, M; Nogami, N; Ohkura, M; Peltz, G; Sakakibara-Konishi, J; Satouchi, M; Seto, T; Suzuki, M; Takahashi, T; Thurm, H | 1 |
| Al-Ahmadie, H; Bajorin, DF; Berger, MF; Bhayankara, A; Boyd, ME; Farooki, A; Garcia-Grossman, IR; Iyer, G; Kim, PH; McCoy, AS; McPherson, V; Milowsky, MI; Ostrovnaya, I; Reardon, B; Regazzi, AM; Rosenberg, JE; Roth, AJ; Scott, SN; Solit, DB; Van Allen, E | 1 |
| Alongi, F; Buglione, M; Costantino, G; Figlia, V; Guerini, AE; Maddalo, M; Magrini, SM; Pasinetti, N; Pedersini, R; Pedretti, S; Pegurri, L; Peretto, G; Salah, E; Simoncini, EL; Triggiani, L; Vassalli, L | 1 |
| Chang, A; Cheng, D; Huang, S; Liu, AT; Sun, P; Tan, X; Wang, G; Wang, J; Wang, Q; Wu, D; Xiang, R; Yang, S; Zhao, S | 1 |
| Amir, E; Desnoyers, A; Kumar, V; Nadler, MB; Saleh, R | 1 |
| Arteaga, CL; Barroso-Sousa, R; Bermejo, B; Cantley, LC; Céliz, P; Ciruelos, E; Garrido-Castro, AC; Gavilá, J; Guo, H; Krop, IE; Li, Y; Lin, NU; Mills, GB; Paré, L; Prat, A; Rodon, J; Saura, C; Savoie, J; Serra, V; Solit, DB; Villagrasa, P; Winer, EP; Xu, Z | 1 |
| Bear, MM; Chapman, SC; Chen, SC; Cortes, J; Hamilton, E; Hardebeck, MC; Hegg, R; Huober, J; Jerusalem, G; Johnston, EL; Lu, Y; Manikhas, A; Martin, M; Ozyilkan, O; Petrakova, K | 1 |
| Chapman, SC; Han, R; Hu, X; Ji, D; Li, W; Shen, W; Sykes, AK; Tao, H; Wang, N; Yang, N; Zhang, J; Zhang, W | 1 |
| Ho, YY; Ji, Y; Lu, Y; Yang, S | 1 |
| He, X; Jiao, XD; Ling, Y; Liu, J; Liu, K; Qin, BD; Song, K; Wu, Y; Xu, AQ; Zang, YS | 1 |
| Cao, J; Che, J; Chen, B; Cheng, G; Dong, X; He, Q; Hu, Y; Jin, Z; Xie, J; Yan, F; Yang, B; You, J; Zhu, H | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, YH; Lee, PH; Tseng, JS; Yang, TY | 1 |
| Bajpai, J; Elamarthi, P; Ghosh, J; Gulia, S; Gupta, S; Kembhavi, Y; Mokal, S; Nandhana, R; Parab, P; Perumal, P; Rath, S | 1 |
| Criscitiello, C; Curigliano, G; Esposito, A; Intra, M; Minucci, S | 1 |
| Baccei, C; Bravo, Y; Broadhead, AR; Bundey, R; Cabrera, G; Chen, A; Correa, LD; Lorrain, DS; Messmer, D; Prasit, P; Stebbins, KJ; Stock, NS | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P | 1 |
| Kwapisz, D | 1 |
| Echavarria, I; Jerez, Y; López-Tarruella, S; Márquez-Rodas, I; Martin, M | 1 |
| Dees, EC; Henderson, GE; Reeder-Hayes, KE; Roberts, MC | 1 |
| Bardia, A; Blouin, GC; Spring, LM; Zangardi, ML | 1 |
| Dizdar, L; Forster, CM; Knoefel, WT; Krieg, A; Raba, K; Schott, M; Verde, PE; Werner, TA | 1 |
| Kim, ES | 1 |
| Alba, E; Auñón, PZ; Bachelot, T; Beck, TJ; Campone, M; Diab, S; Esteva, FJ; Gil-Gil, M; Janni, W; Kral, Z; Lopez, R; Miller, M; Pluard, TJ; Richards, P; Ryvo, L; Sutradhar, S; Tsai, M; Ward, P | 1 |
| Alebachew, E; Beaver, JA; Bi, Y; Bloomquist, E; Blumenthal, GM; Chang, CJG; Fu, W; Goldberg, KB; Ibrahim, A; Liu, Q; Palmby, TR; Patel, P; Pazdur, R; Pierce, WF; Shah, A; Sridhara, R; Tang, S; Tilley, A; Yu, J; Zhao, P | 1 |
| Burris, HA | 1 |
| Banskota, S; Gautam, J; Jeon, YH; Jeong, BS; Kim, JA; Lee, H; Lee, YJ | 1 |
| Afghahi, A; Diamond, JR; Shagisultanova, E; Weiss, J | 1 |
| Hou, TY; Hsiao, YP; Huang, SJ; Ko, JL; Leong, PY; Lu, CT | 1 |
| De Angelis, C; Ekinci, E; Flajc, G; Liu, X; Rascon, K; Trivedi, MV | 1 |
| Augereau, P; Berton Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Robert, M | 1 |
| Camidge, DR; Honce, JM; Lindquist, DL; Sakamoto, MR | 1 |
| Coleman, N; Popat, S; Wotherspoon, A; Yousaf, N | 1 |
| Artis, DR; Bollag, G; Bremer, R; Burton, EA; Carias, H; Habets, G; Hirth, P; Hurt, CR; Ibrahim, PN; Lin, P; Marimuthu, A; Matusow, B; Nespi, M; Nguyen, H; Nolop, K; Oh, A; Powell, B; Shellooe, R; Spevak, W; Tesch, GH; Tsang, G; West, BL; Wu, G; Zhang, C; Zhang, J; Zhang, KY; Zhang, Y | 1 |
| Aimone, P; Canon, JL; De Braud, F; De Pas, T; Di Tomaso, E; Dy, GK; Felip, E; Gray, JE; Gridelli, C; Grossi, F; Reck, M; Roussou, P; Soria, JC; Su, WC; Thongprasert, S; Vansteenkiste, JF; Vidam, GA; Wang, YA; Yoshioka, H | 1 |
| Lorimer, E; Tyburski, MD; Williams, CL; Wilson, JM | 1 |
| Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L | 1 |
| Bellmunt, J; Choueiri, TK; De Velasco, G; Harshman, L; Hirsch, M; McDermott, DF; McKay, RR; Rosenberg, JE; Signoretti, S; Sweeney, C; Vaishampayan, U; Van Allen, EM; Walsh, M; Werner, L | 1 |
| Beckmann, RP; Beeram, M; Chan, EM; Cronier, DM; Flaherty, KT; Frenzel, M; Fulford, AD; Gandhi, L; Goldman, JW; Hilton, JF; Kulanthaivel, P; Li, LQ; Martinez, R; Nasir, A; Nguyen, TS; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rosen, LS; Schade, AE; Shapiro, GI; Tolaney, SM; Tolcher, AW; Wen, PY | 1 |
| Anderson, N; Andrade, K; Fornetti, J; McHale, M; Miller, SC; Randall, RL; Waltz, SE; Welm, AL; Zhao, L | 1 |
| Dai, Y; Siemann, DW | 1 |
| Bae, K; Dai, Y; Pampo, C; Siemann, DW | 1 |
| Blackwell, BN; Lijinsky, W; Reuber, MD | 1 |
11 review(s) available for alpha-aminopyridine and Metastase
| Article | Year |
|---|---|
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: A combined analysis of phase III randomized controlled trials.
Topics: Aminopyridines; Breast Neoplasms; Cardiac Conduction System Disease; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Purines; Randomized Controlled Trials as Topic; Risk Factors | 2021 |
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasm Metastasis; Network Meta-Analysis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic | 2020 |
Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Purines; Receptor, ErbB-2 | 2017 |
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Evaluation, Preclinical; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2017 |
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Metastasis; Neutropenia; Postmenopause; Purines; Receptor, ErbB-2 | 2017 |
Abemaciclib: First Global Approval.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinases; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; United States; United States Food and Drug Administration | 2017 |
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Design; Female; Humans; Neoplasm Metastasis; Progression-Free Survival; Purines | 2018 |
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Premenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2019 |
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors | 2019 |
11 trial(s) available for alpha-aminopyridine and Metastase
| Article | Year |
|---|---|
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Evaluation; Female; Follow-Up Studies; Humans; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptors, Estrogen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Viscera | 2020 |
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Aminopyridines; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Urologic Neoplasms | 2020 |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Patient Safety; Protein Kinase Inhibitors; Proteomics; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Progression-Free Survival; Tamoxifen; Treatment Outcome | 2021 |
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.
Topics: Aged; Aminopyridines; Benzimidazoles; China; Female; Humans; Male; Neoplasm Metastasis; Neoplasms | 2021 |
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Topics: Adult; Age Factors; Aged; Aminopyridines; Antineoplastic Agents; Area Under Curve; Body Weight; Breast Neoplasms; Drug Interactions; Female; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolic Clearance Rate; Metabolic Networks and Pathways; Middle Aged; Models, Biological; Neoplasm Metastasis; Neutrophils; Purines; Racial Groups; Receptor, ErbB-2; Receptors, Progesterone; Sex Factors | 2021 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate | 2017 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2018 |
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Topics: Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases | 2015 |
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Morpholines; Neoplasm Metastasis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
31 other study(ies) available for alpha-aminopyridine and Metastase
| Article | Year |
|---|---|
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms | 2021 |
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2022 |
MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis.
Topics: Aminopyridines; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Neoplasms, Experimental; Pyrroles; Signal Transduction | 2019 |
Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Creatinine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; New South Wales; Purines; Receptor, ErbB-2; Retrospective Studies | 2019 |
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Japan; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Purines; Treatment Outcome | 2020 |
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Topics: Aged; Aged, 80 and over; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Hypercholesterolemia; Lactams; Lactams, Macrocyclic; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles | 2020 |
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
Topics: Aminopyridines; Breast Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Ileitis; Molecular Targeted Therapy; Neoplasm Metastasis; Neutropenia; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiotherapy; Retrospective Studies | 2020 |
Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dipeptides; Female; Heat-Shock Proteins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Neoplasm Metastasis; Phosphorylation; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; Pyridines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2020 |
Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.
Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Colorectal Neoplasms; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Neoplasm Metastasis; Piperidines; Pyrazoles; Treatment Outcome | 2021 |
Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice, Inbred BALB C; Molecular Structure; Neoplasm Metastasis; Neoplasms; Rats, Sprague-Dawley; Signal Transduction; Structure-Activity Relationship | 2021 |
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrazoles; Retrospective Studies | 2021 |
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
Topics: Aged; Aminopyridines; Breast Neoplasms; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2021 |
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factors; Humans; Mice; Neoplasm Metastasis; Neovascularization, Physiologic; PPAR alpha; Rats; Sulfonamides | 2017 |
Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Decision Making; Female; Humans; Informed Consent; Morpholines; Motivation; Neoplasm Metastasis; Protein Kinase Inhibitors; Qualitative Research; Research Subjects | 2017 |
Ribociclib (Kisqali) for advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Purines; Signal Transduction; Treatment Outcome | 2017 |
CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antigens, CD; Benzylamines; Cadherins; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Chemokine CXCL12; Child; Cyclams; Epithelial-Mesenchymal Transition; Female; Fibroblast Growth Factor 9; Gene Expression; GPI-Linked Proteins; Heterocyclic Compounds; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Prognosis; Receptors, CXCR; Receptors, CXCR4; Recombinant Proteins; Retrospective Studies; Snail Family Transcription Factors; Survival Rate; Thyroid Neoplasms; Tissue Array Analysis; Tumor Burden; Vimentin; Young Adult | 2017 |
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Research Design; Treatment Outcome | 2018 |
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Topics: Aminopyridines; Animals; Cathepsins; Cell Proliferation; Cell Survival; Chickens; Chorioallantoic Membrane; Down-Regulation; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; src-Family Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Carcinoma, Lobular; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Ganoderma; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaV; Male; Melanoma, Experimental; Mice, Inbred C57BL; Neoplasm Metastasis; Signal Transduction | 2018 |
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Crizotinib; Drug Approval; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Neoplasm Metastasis; Organophosphorus Compounds; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome | 2019 |
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pyrazoles; Tomography, X-Ray Computed | 2019 |
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.
Topics: Aminopyridines; Animals; Cell Survival; Chromatography, Affinity; Crystallization; Escherichia coli; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Inflammation; Macrophages; Mast Cells; Models, Molecular; Molecular Structure; Mutation, Missense; Neoplasm Metastasis; Oncogene Protein gp140(v-fms); Osteoclasts; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sf9 Cells; Spodoptera | 2013 |
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Aminopyridines; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cell Movement; Female; GTP-Binding Protein alpha Subunits, Gs; Humans; Isoproterenol; Neoplasm Metastasis; Phenotype; Phosphorylation; Propranolol; Protein Prenylation; Protein Transport; rap GTP-Binding Proteins; Receptors, Adrenergic, beta; Signal Transduction | 2015 |
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Single-Agent Abemaciclib Active in Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2016 |
RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.
Topics: Aminopyridines; Animals; Bone and Bones; Estrogens; Female; Humans; Mice; Mice, Transgenic; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Osteoblasts; Osteoclasts; Osteoporosis; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2017 |
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Topics: Aminopyridines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridones; Signal Transduction; Small Molecule Libraries | 2010 |
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Movement; Female; Humans; Mice; Mice, Inbred C3H; Neoplasm Invasiveness; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; Pyridones; Sarcoma, Experimental; Signal Transduction | 2012 |
Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride.
Topics: Aminopyridines; Animals; Carcinogens; Drug Interactions; Female; Liver Neoplasms, Experimental; Male; Methapyrilene; Neoplasm Metastasis; Nitrites; Rats | 1980 |